GBR-13069

From WikiMD's WELLNESSPEDIA

Glycogen Storage Disease Type I[edit]

Diagram illustrating the biochemical pathway affected in Glycogen Storage Disease Type I.

Glycogen Storage Disease Type I (GSD I), also known as von Gierke disease, is a metabolic disorder characterized by the accumulation of glycogen in the liver and kidneys due to a deficiency in the enzyme glucose-6-phosphatase. This enzyme is crucial for the final step of gluconeogenesis and glycogenolysis, which is the conversion of glucose-6-phosphate into free glucose.

Pathophysiology[edit]

GSD I is caused by mutations in the G6PC gene, which encodes the glucose-6-phosphatase enzyme. The deficiency of this enzyme leads to the inability to convert glucose-6-phosphate into glucose, resulting in the accumulation of glycogen and fat in the liver and kidneys. This accumulation causes hepatomegaly and nephromegaly, and the inability to maintain normal blood glucose levels leads to hypoglycemia.

Clinical Features[edit]

Patients with GSD I typically present in infancy with symptoms such as severe hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. The hypoglycemia can lead to seizures and developmental delay if not managed properly. Other features include a "doll-like" facial appearance, short stature, and delayed puberty.

Diagnosis[edit]

The diagnosis of GSD I is based on clinical presentation, biochemical tests, and genetic testing. Biochemical tests reveal hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. Genetic testing can confirm mutations in the G6PC gene.

Management[edit]

Management of GSD I focuses on maintaining normal blood glucose levels to prevent hypoglycemia. This is achieved through frequent feedings of cornstarch and a high-carbohydrate diet. In some cases, allopurinol is used to manage hyperuricemia, and lipid-lowering agents may be used to control hyperlipidemia.

Prognosis[edit]

With proper management, individuals with GSD I can lead relatively normal lives, although they may have an increased risk of developing hepatic adenomas and renal disease later in life.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.